KIT binds type II TKIs

Stable Identifier
R-HSA-9669854
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

KIT can be bound and inhibited by class II tyrosine kinase inhibitors including imatinib, sunitinib, regorafenib and others. Type II inhibitors bind to the inactive conformation of the kinase and prevent its activation (reviewed in Roskoski, 2018; Abbaspour Babaei et al, 2016; Klug et al, 2018).

Literature References
PubMed ID Title Journal Year
29704617 The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
27536065 Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

Abbaspour Babaei, M, Kamalidehghan, B, Saleem, M, Huri, HZ, Ahmadipour, F

Drug Des Devel Ther 2016
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Klug, LR, Kent, JD, Heinrich, MC

Pharmacol. Ther. 2018
Participants
Participant Of
Orthologous Events
Authored
Reviewed
Created
Cite Us!